Mature T-cell and NK-cell lymphomas: updates on molecular genetic features

Lewis, Natasha; Sardana, Rohan; Doğan, Ahmet

doi:10.1007/s12185-023-03537-7

Cited by 4 publications

(3 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 The constitutively activated ALK drives cell proliferation and inhibits apoptosis through activation of signaling pathways (including JAK/STAT, PI3K/AKT), and promotes immune evasion via STAT3-mediated PD-L1 expression. 27 Genomic studies of ALK+ ALCL have also reported mutations in TP53 (11%), as well as in genes involved in epigenetic modification (EP300, KMT2D), TCR signaling, and NOTCH1 pathways. 28,29 In particular, NOTCH pathway activation represents a second-line therapeutic target, as suppression of NOTCH1 expression with γ-secretase inhibitors led to apoptosis in ALK inhibitor-resistant ALCL cell lines.…”

Section: Alk+ Alclmentioning

confidence: 99%

“…The most common chromosomal translocation is t (2, 5) that partners ALK on chromosome 2 with NPM1 resulting in a constitutively active kinase 26 . The constitutively activated ALK drives cell proliferation and inhibits apoptosis through activation of signaling pathways (including JAK/STAT, PI3K/AKT), and promotes immune evasion via STAT3‐mediated PD‐L1 expression 27 . Genomic studies of ALK+ ALCL have also reported mutations in TP53 (11%), as well as in genes involved in epigenetic modification ( EP300 , KMT2D ), TCR signaling, and NOTCH1 pathways 28,29 .…”

Section: Molecular Pathogenesis Of Ptcl Subtypesmentioning

confidence: 99%

See 1 more Smart Citation

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Ong,

Zain

2024

American J Hematol

View full text Add to dashboard Cite

IntroductionAggressive T‐cell lymphomas continue to have a poor prognosis. There are over 30 different subtypes of peripheral T‐cell lymphoma (PTCL), and we are now beginning to understand the differences between the various subtypes beyond histologic variations.Molecular Pathogenesis of Various Subtypes of PTCLGene expression profiling and other molecular techniques have enabled deeper understanding of differences in various subtypes as reflected in the latest 5th WHO classification of PTCL. It is becoming increasingly clear that therapeutic approaches that target specific cellular pathways are needed to improve the clinical outcomes of PTCL.Targeted TherapiesThere are many targeted agents currently in various stages of clinical trials for PTCL that take advantage of the differential expression of specific proteins or receptors in PTCL tumors. This includes the CD30 directed antibody drug conjugate brentuximab vedotin. Other notable targets are phosphatidylinositol 3‐kinase inhibitors, histone deacetylase inhibitors, CD25, and chemokine receptor 4. Anaplastic lymphoma kinase (ALK) inhibitors are promising for ALK expressing tumors.ImmunotherapiesAllogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL. The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T‐cell lymphoma. Bispecific antibody‐based treatments and chimeric antigen receptor cell‐based therapies are in clinical trials.

show abstract

Section: Alk+ Alclmentioning

confidence: 99%

Section: Molecular Pathogenesis Of Ptcl Subtypesmentioning

confidence: 99%

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Ong,

Zain

2024

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Extranodal entities, as detailed by Lewis, Zhou and Dogan, 22 with a clinical lens provided by Stuver, Epstein-Peterson and Horwitz, 23 are identified by their primary location. They constitute a diverse and rare group of diseases with a limited number of dedicated clinical trials, making therapeutic advancement very challenging.…”

mentioning

confidence: 99%

Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization

Savage,

De Leval

2023

haematol

View full text Add to dashboard Cite

A genetic profiling guideline to support diagnosis and clinical management of lymphomas

Sánchez-Beato,

Méndez,

Guirado

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassification, patient risk stratification, and prediction of treatment response. Lymphomas are characterized by very few recurrent and disease-specific mutations, and most entities have a heterogenous genetic landscape with a long tail of recurrently mutated genes. Most of these occur at low frequencies, reflecting the clinical heterogeneity of lymphomas. Multiple studies have identified genetic markers that improve diagnostics and prognostication, and next-generation sequencing is becoming an essential tool in the clinical laboratory. This review provides a “next-generation sequencing” guide for lymphomas. It discusses the genetic alterations of the most frequent mature lymphoma entities with diagnostic, prognostic, and predictive potential and proposes targeted sequencing panels to detect mutations and copy-number alterations for B- and NK/T-cell lymphomas.

show abstract

Mature T-cell and NK-cell lymphomas: updates on molecular genetic features

Cited by 4 publications

References 161 publications

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization

A genetic profiling guideline to support diagnosis and clinical management of lymphomas

Contact Info

Product

Resources

About